Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 9,522	$ 12,024
Trade accounts receivable, net of allowance for doubtful accounts of $170 and $122 at January 31, 2020 and July 31, 2019, respectively	325	450
Due from Rafael Pharmaceuticals	118	280
Prepaid expenses and other current assets	326	507
Total current assets	10,291	13,261
Property and equipment, net	48,250	48,733
Investments - Rafael Pharmaceuticals	70,018	70,018
Investments - Other Pharmaceuticals	2,000	2,000
Investments - Hedge Funds	5,645	5,125
Deferred income tax assets, net	7	19
In-process research and development and patents	1,575	1,575
Other assets	1,450	1,412
TOTAL ASSETS	139,236	142,143
CURRENT LIABILITIES
Trade accounts payable	569	795
Accrued expenses	579	605
Other current liabilities	48	27
Total current liabilities	1,196	1,427
Due to Related Party	29	65
Convertible note, net of discount of $0 and $54 - Related Party		14,946
Other liabilities	92	292
Accrued interest on convertible note - Related Party		649
TOTAL LIABILITIES	1,317	17,379
COMMITMENTS AND CONTINGENCIES
EQUITY
Additional paid-in capital	128,843	112,898
Accumulated deficit	(8,691)	(5,840)
Accumulated other comprehensive income related to foreign currency translation adjustment	3,756	3,784
Total equity attributable to Rafael Holdings, Inc.	124,065	110,981
Noncontrolling interests	13,854	13,783
TOTAL EQUITY	137,919	124,764
TOTAL LIABILITIES AND EQUITY	139,236	142,143
Class A common stock
EQUITY
Common stock value	8	8
TOTAL EQUITY	8	8
Class B common stock
EQUITY
Common stock value	149	131
TOTAL EQUITY	$ 149	$ 131